Evidence map›Paper›PMID 36121874›Full record

ArticlePLoS pathogens2022

The secreted protein Cowpox Virus 14 contributes to viral virulence and immune evasion by engaging Fc-gamma-receptors.

Ravi F Iyer, David M Edwards, Philipp Kolb, Hans-Peter Raué, Chris A Nelson, Megan L Epperson, Mark K Slifka, Jeffrey C Nolz, Hartmut Hengel, Daved H Fremont and 1 more

Open access · goldAbstract read
In one paragraph

Article in PLoS pathogens, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.5field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 2 countries.

Ravi F IyerVaccine and Gene Therapy Institute, Oregon Health and Science University, Beaverton, Oregon, United States of America.
David M EdwardsVaccine and Gene Therapy Institute, Oregon Health and Science University, Beaverton, Oregon, United States of America.
Philipp KolbInstitute of Virology, Medical Center, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
Hans-Peter RauéOregon National Primate Research Center, Oregon Health & Science University, Beaverton, Oregon, United States of America.
Chris A NelsonDepartment of Pathology & Immunology, Washington University School of Medicine in St. Louis, St. Louis, Missouri, United States of America.
Megan L EppersonDepartment of Pathology & Immunology, Washington University School of Medicine in St. Louis, St. Louis, Missouri, United States of America.
Mark K SlifkaOregon National Primate Research Center, Oregon Health & Science University, Beaverton, Oregon, United States of America.
Jeffrey C NolzDepartment of Molecular Microbiology and Immunology, Oregon Health & Science University, Portland, Oregon, United States of America.
Hartmut HengelInstitute of Virology, Medical Center, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
Daved H FremontDepartment of Pathology & Immunology, Washington University School of Medicine in St. Louis, St. Louis, Missouri, United States of America.
Klaus FrühVaccine and Gene Therapy Institute, Oregon Health and Science University, Beaverton, Oregon, United States of America.ORCID 0000-0001-8014-3877
Oregon Health & Science University · USWashington University in St. Louis · USOregon National Primate Research Center · USUniversity of Freiburg · DE

Funding

Upgrade of confocal microscopy at the Oregon National Primate Research CenterP51OD011092 · OD · OREGON HEALTH & SCIENCE UNIVERSITY · PI Bonnie J. Nagel · 2012 to 2026
$203.9M
An Advanced Vaccine Candidate To Prevent Zika Virus InfectionR01AI132186 · NIAID · OREGON HEALTH & SCIENCE UNIVERSITY · PI SLIFKA, MARK K · 2017 to 2021
$6.9M
T Cell Control by Cowpoxvirus U19AI109948 · NIAID · WASHINGTON UNIVERSITY · PI YOKOYAMA, WAYNE M. · 2014 to 2018
$6.4M
REGULATION OF MEMORY T CELL TRAFFICKING BY CORE 2 O-GLYCAN SYNTHESISR01AI132404 · NIAID · OREGON HEALTH & SCIENCE UNIVERSITY · PI NOLZ, JEFFREY C. · 2017 to 2021
$2.0M
NIAID NIH HHS R01 AI132186NIAID NIH HHS R01 AI132404NIAID NIH HHS U19 AI109948NIH HHS P51 OD011092
6 · The paper itself

Abstract

The genome of cowpoxvirus (CPXV) could be considered prototypical for orthopoxviridae (OXPV) since it contains many open reading frames (ORFs) absent or lost in other OPXV, including vaccinia virus (VACV). These additional ORFs are non-essential for growth in vitro but are expected to contribute to the broad host range, virulence and immune evasion characteristics of CPXV. For instance, unlike VACV, CPXV encodes proteins that interfere with T cell stimulation, either directly or by preventing antigen presentation or co-stimulation. When studying the priming of naïve T cells, we discovered that CPXV, but not VACV, encodes a secreted factor that interferes with activation and proliferation of naïve CD8+ and CD4+ T cells, respectively, in response to anti-CD3 antibodies, but not to other stimuli. Deletion mapping revealed that the inhibitory protein is encoded by CPXV14, a small secreted glycoprotein belonging to the poxvirus immune evasion (PIE) family and containing a smallpoxvirus encoded chemokine receptor (SECRET) domain that mediates binding to chemokines. We demonstrate that CPXV14 inhibition of antibody-mediated T cell activation depends on the presence of Fc-gamma receptors (FcγRs) on bystander cells. In vitro, CPXV14 inhibits FcγR-activation by antigen/antibody complexes by binding to FcγRs with high affinity and immobilized CPXV14 can trigger signaling through FcγRs, particularly the inhibitory FcγRIIB. In vivo, CPXV14-deleted virus showed reduced viremia and virulence resulting in reduced weight loss and death compared to wildtype virus whereas both antibody and CD8+ T cell responses were increased in the absence of CPXV14. Furthermore, no impact of CPXV14-deletion on virulence was observed in mice lacking the inhibitory FcγRIIB. Taken together our results suggest that CPXV14 contributes to virulence and immune evasion by binding to host FcγRs.

Indexed as

Cowpox virusImmune EvasionAnimalsGlycoproteinsMiceReceptors, ChemokineReceptors, IgGVaccinia virusVirulenceGlycoproteinsReceptors, ChemokineReceptors, IgG

Identifiers

PMID36121874
PMCPMC9521928
OpenAlexW4296330105

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.